The heterogeneity of studies relates to the study populations and inclusion criteria (in both the “any cancer” and breast cancer groups of articles), particularly with respect to patient age ranges included, years of inclusion, molecular subtypes of disease included (including HR and HER2 status), stages of disease included, and sex/gender of patients included. Here, ERBB2 is linked to breast carcinoma.